12:18 PM EST, 01/17/2025 (MT Newswires) -- Johnson & Johnson's ( JNJ ) Q4 earnings and revenue estimates were nudged higher before results on Wednesday, BofA Securities said Friday in a report.

The firm's estimate for per-share earnings rose to $2.08 from $2.03 with revenue forecast at $22.61 billion, up from $22.52 billion, the report said.

In 2025 and 2026, BofA said estimates are "slightly lower" with sales in the medical technology segment seen easing, and underlying EPS estimates are down on "lower revenues, higher currency headwinds, and tax."

BofA said the focus of the Q4 earnings call will likely include an indication of the impact of the acquisition of Intra-Cellular Therapies ( ITCI ) , along with currency fluctuations seen as a "material headwind to reported sales and EPS."

BofA cut the price target on Johnson & Johnson ( JNJ ) to $160 from $166 and reiterated its neutral rating.

Price: 147.24, Change: -0.53, Percent Change: -0.36